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ABSTRACT
Glioblastoma Multiforme (GBM) is a highly prevalent and deadly brain malignancy 
characterized by poor prognosis and restricted disease management potential. Despite 
the success of nanocarrier systems to improve drug/gene therapy for cancer, active 
targeting specificity remains a major hurdle for GBM. Additionally, since the brain is 
a multi-cell type organ, there is a critical need to develop an approach to distinguish 
between GBM cells and healthy brain cells for safe and successful treatment. In this 
report, we have incorporated hyaluronic acid (HA) as an active targeting ligand for 
GBM. To do so, we employed HA conjugated liposomes (HALNPs) to study the uptake 
pathway in key cells in the brain including primary astrocytes, microglia, and human 
GBM cells. We observed that the HALNPs specifically target GBM cells over other 
brain cells due to higher expression of CD44 in tumor cells. Furthermore, CD44 driven 
HALNP uptake into GBM cells resulted in lysosomal evasion and increased efficacy of 
Doxorubicin, a model anti-neoplastic agent, while the astrocytes and microglia cells 
exhibited extensive HALNP-lysosome co-localization and decreased antineoplastic 
potency. In summary, novel CD44 targeted lipid based nanocarriers appear to be 
proficient in mediating site-specific delivery of drugs via CD44 receptors in GBM cells, 
with an improved therapeutic margin and safety.
INTRODUCTION
Glioblastoma Multiforme (GBM) is the most 
aggressive, lethal, and prevalent brain malignancy with 
over 10,000 new cases diagnosed in the United States each 
year [1, 2] GBM is specifically a grade IV astrocytoma 
histologically defined by abnormal cellularity, mitotic 
activity, vascular proliferation, and necrosis leading 
to a highly mobile and invasive phenotype capable of 
infiltrating surrounding brain tissue [3]. Consequently, 
GBM is characterized by poor prognosis, restricted disease 
management potential, and a less than 1 year median 
survival rate [4]. Current widespread clinical treatment 
options for GBM include radiation therapy, chemotherapy 
with antineoplastic agents, and maximal tumor resection 
[5]. However, these treatment measures instigate systemic 
toxic effects to healthy tissue, are limited in potency by 
intrinsic resistance pathways, require regular invasive dose 
regimens, and overall do not provide improved long-term 
quality of life for the patient. Therefore there is a critical 
need to develop a novel approach that can overcome 
current limitations and alleviate the burden of GBM. 
Brain tumors are categorized according to the glial 
type they are most histologically similar, location of the 
tumor, and overall phenotypical behavior [6]. Brain tumor 
microenvironment also consists of other cells including 
glial cells (astrocytes and microglia) that are a class of 
non-neuronal brain cells. Astrocytomas including GBM 
are most similar to astrocytes, and therefore it is crucial 
to ensure that any targeting approach developed for GBM 
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treatment must be able to 1) distinguish between GBM 
cancer cells and healthy astrocytes, and 2) evade rapid 
phagocytosis by microglial cells. A promising method for 
active targeting to cancer cells is the exploitation of the 
differential expression of CD44. CD44 is a cell membrane-
bound surface receptor that mediates cell-cell and 
cell-extracellular matrix (ECM) communication [7–11], 
and has been found to be increased in numerous cancer 
types including breast [12], lung [13], colorectal [14] 
tumors compared to basal expression in equivalent healthy 
tissue [15]. Hyaluronic acid (HA), a main component of 
the ECM, is a natural ligand to CD44 has been used as 
a targeting moiety for CD44 overexpressing cancers, 
facilitating preferential uptake and potent therapeutic 
efficacy [16–22]. Recently, CD44 has also been found to 
be increased in glioma cells compared to healthy astrocytes 
[23, 24], and has been implicated to directly impact glioma 
invasion [24, 25]. Although these findings are extremely 
exciting, only a few studies involving an HA decorated 
nanocarrier have been examined as a potential CD44 
targeted GBM therapy [26, 27]. Furthermore, no studies 
to date have performed an in-depth analysis probing the 
true merit of HA as a natural ligand to preferentially bind 
and internalize into GBM cells over healthy glial cells.
Recently, liposomes and lipid-based nanocarriers 
have demonstrated robust efficacy in drug and gene 
therapy comprising precise coordinates of the body 
such as the brain [28–31]. The successful application of 
liposome nanocarriers has been catalyzed by targeted 
delivery and subsequent preferential intracellular uptake 
via either passive (diffusion driven accumulation and local 
cell uptake) or active (explicit cell receptor driven uptake) 
mechanisms [32–37]. Although passive approaches have 
been employed extensively via implementation of the 
enhanced permeability and retention (EPR) effect, the 
advent of biomarker identification coupled to pathological 
categorization has greatly improved the efficacy, 
selectivity, and overall safety of liposome therapeutic 
delivery.  From this approach, liposomes can be surface 
decorated with receptor recognition ligands including 
antibodies, aptamers, peptides, and integrins to facilitate 
targeting of specific biomarkers that are identified in 
disease states. For example, EGFR [38], Folate Receptor 
[39, 40], and HER2 [41] directed nanotherapies have 
significantly improved global cancer treatment via cell 
specific endocytosis of therapeutic cargo. In regards to 
GBM therapy, a wide array of active recognition ligands 
have been utilized to date including the peptide sequences 
IL13 [42, 43], CGKRK [44], Pep1 [45], activatable low 
molecular weight protamine [46], and chlorotoxin [47], 
antibodies such as EGFRvIII [48], low density lipoprotein 
receptor related proteins [49, 50], and the GMT8 aptamer 
[51]. These targeting moieties have exploited GBM cell 
specific membrane signatures with varying levels of 
success to deliver numerous drug types including the 
chemotherapeutics doxorubicin [43] and paclitaxel [49], 
antisense oligonucleotides/silencing RNAs [4, 47], peptide 
based therapeutics such as KLAKLAK [44], inhibitors 
[52, 53], and other therapeutic cargo types [54–56] for 
GBM management. While encouraging, there is limited 
knowledge on how the different cell types in the brain, 
specifically glial cells, influence the uptake selectivity of 
active GBM targeted therapy.
In this study we investigated the potential of 
implementing HA as a surface bound targeting moiety 
for liposome GBM therapy. To do so, we employed 
our previously optimized high molecular weight HA 
conjugated liposomes (HALNPs) to study the uptake 
pathway in key cells in the brain including primary 
astrocytes, microglia (MG), and human GBM cells [22, 57]. 
Specifically, three GBM cells lines were utilized: invasive 
and non-tumorigenic (A172 cells), non-invasive and slightly 
tumorigenic (U251), and invasive and highly tumorigenic 
(U87MG). From this approach, we determined the rate and 
overall extent of HA coated liposome intracellular delivery 
to astrocytes, microglial, and GBM cells, as well as probed 
the capacity of each cell type to implement CD44 stimulated 
uptake and the resultant effect on nanoparticle endolysosomal 
fate. A potency assay employing doxorubicin in both the free 
form and encapsulated inside HA coated liposomes was also 
performed to validate the robust influence of targeted therapy 
on the selectivity and efficacy of GBM treatment. We believe 
this information is significant in the development of novel 
GBM nano-therapies, and will catalyze the usage of CD44 
targeting for the treatment of GBM.
RESULTS AND DISCUSSION
Design and characterization of hyaluronic acid 
coated liposomes (HALNPs)
To investigate the potential of using hyaluronic 
acid (HA) as a targeting ligand for GBM therapy, we 
first engineered an HA conjugated nanocarrier system 
following our previously optimized protocol [22, 57]. 
The liposome nanoparticles (LNPs) were made from the 
biocompatible constituents PC, DPPE, and CHOL in a 
3:1:1 molar ratio and doped with 0.15 mass % fluorescent 
cholesterol as a tracker. The LNPs were surface decorated 
with high molecular weight HA (HALNPs) via an EDC 
facilitated amide bond formation between the carboxyl 
group of the HA and the primary amine of the DPPE 
lipid head group as seen in Figure 1A. Initial validation 
of significant surface functionalization was determined 
by size and charge characterization (Table 1). Bare 
LNPs were 95.0 ± 0.7 nm in hydrodynamic diameter 
with a polydispersity index (PI) of 0.032, and increased 
in size to 126.6 ± 5.62 nm with a PI of 0.157 following 
the crosslinking of HA. The charge of the particles also 
dropped from −5.74 ± 2.24 to −23.64 ± 1.49 mV due to 
the presence of the excess carboxylic acid groups of the 
HA on the surface of the liposomes. HA surface decoration 
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was also confirmed by TEM analysis visually depicting 
the increase in nanoparticle size and surface roughness 
(Figure 1B). High magnification confocal microscopy 
was also employed to demonstrate the fluorescent nature 
of the HALNPs due to the fluorescent tracker in the lipid 
bilayer (Figure 1C). The rationale for using high molecular 
weight HA (1.65 MDa) to the LNPs was previous studies 
have demonstrated that high molecular weight HA is anti-
inflammatory and has a high binding affinity to CD44 
[19]. Also from our previous study, we demonstrated that 
crosslinking the LNPs with high MW Hyaluronic Acid 
(HA) did not increase the particle size and underwent no 
significant change in net surface charge after lyophilization 
[22]. We also demonstrated that encapsulation of a range 
of molecular weight of FITC-tagged Dextran (FD) (10, 20, 
and 70 kDa) as model drugs did not change the HALNP 
size. Following nanoparticle design and characterization, 
we then utilized our HALNP nanocarrier system to 
examine uptake rate and extent in both GBM and healthy 
glial cells. 
Preferential uptake of HALNPs by glioblastoma 
cells over healthy glial cells
The brain is a multi-cell type organ comprising 
primarily of neurons and a spectrum of glial cells. 
Consequently, any targeted drug delivery to the brain must 
facilitate preferential uptake by the cell of interest in order 
to achieve higher potency, reduce offsite toxicity, and 
overall promote a positive therapeutic outcome. To test the 
true merit of HA driven active targeting for GBM therapy, 
we utilized comprehensive cell cultures consisting of 
primary rat astrocytes, primary mouse microglia cells, and 
human GBM cells. In addition to being the most abundant 
cell type, astrocytes were included in our model system 
because primary astrocytoma brain tumors including 
GBM are most similar to astrocyte cells and therefore they 
represent a targeting hurdle. Furthermore, we included 
primary astrocytes from both the cortical (Cort Astro) 
and cerebellum (Cereb Astro) regions of the brain due to 
their high correlation with GBM onset [58]. Microglial 
Figure 1: Hyaluronic acid (HA) decorated lipid nanocarrier fabrication overview and characterization. (A) Lipid 
nanoparticles (LNPs) were surface functionalized with HA (HALNPs) via EDC facilitated amide bond formations. The LNPs were 
characterized via (B) transmission electron microscopy (TEM) pre and post HA surface crosslinking to confirm significant surface 
decoration, and (C) by high magnification confocal microscopy to illustrate the fluorescent nature of the HALNPs due to the lipid bilayer 
incorporated fluorescent tracker (495 ex.; 520 em.). The TEM scale bars at 250 nm and the scale bar for the confocal microscopy is 1 micron.
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(MG) cells were incorporated in our model system 
because they are scavenger cells that readily degrade 
any foreign material in the brain [59], and thus must be 
evaded for optimal treatment efficacy. Lastly, GBM cells 
were integrated into our brain model to represent the 
delivery target. Specifically, three GBM cells lines were 
selected to obtain results spanning different source donors 
as well as to probe the potential of treating GBM cells 
with varying phenotypical properties such as invasive and 
non-tumorigenic (A172 cells), non-invasive and slightly 
tumorigenic (U251), and invasive and highly tumorigenic 
(U87MG) [60].
The targeting capacity of HA was directly assessed 
in GBM cells along with MG and astrocytes using flow 
cytometry analysis (Figure 2, Supplementary Figure 2). 
Flow cytometry was chosen due to its ability to examine 
uptake simultaneously in both a population wide 
(Figure 2B) and per cell basis (Figure 2C). Prior to 
analysis, all six cell types were seeded at low density to 
ensure the uptake data acquired was indicative of per-cell 
behavior (Supplementary Figure 3). Following a three 
hour incubation time with the HALNPs, the cerebellum 
and cortical astrocytes exhibited 29.3% and 32% positive 
populations for HALNP uptake, and a 10 and 6.7 fold 
change in per cell fluorescence, respectively. At the same 
time point, the MG cells had a 37.7% positive population, 
and a 14.5 fold change in per cell fluorescence, while the 
A172, U251, and U87MG GBM cells achieved 77.7%, 
34.5%, and 52.5% positive populations with 153.4, 87.3, 
and 133.3 fold change in per cell fluorescence, respectively. 
This significant difference in HALNP uptake between the 
glial (astrocytes and microglial) and the GBM cells was 
further corroborated by quantitative confocal microscopy 
at the analogous three hour time point (Figure 2D, 
Supplementary Figure 3). 
Flow cytometry was also performed after a 12 hour 
incubation with HALNPs to reveal if the differential 
cell uptake patterns were transient or long lived via a 
preferential mechanism. Following this incubation time, 
the cerebellum and cortical astrocytes had a 57.8% and 
52.9% positive population and a 43.8 and a 28.6 fold 
change in per cell fluorescence, respectively. Furthermore, 
the MG cells reached a 57.7% population and a 54.3 
fold change in fluorescence, while the A172, U251, and 
U87MG GBM cells attained 84.1%, 61.8%, and a 55% 
positive populations with 314.6, 233.3 and 161.7 fold 
change in per cell fluorescence, respectively. This set of 
experiments demonstrated the potential of employing 
HALNPs for targeting GBM cells. In addition, the results 
obtained seem to indicate that HA may be binding with 
the GBM cells differently than the healthy glial cells to 
facilitate preferential intracellular delivery. We have 
earlier shown that CD44 promotes uptake of HA coated 
liposomes in breast cancer over corresponding healthy 
breast tissue [22], and thus we hypothesize this receptor 
endocytosis route may be a driving force for favored GBM 
uptake. 
Differential expression of CD44 facilitates active 
targeting of glioblastoma cells
CD44 is a cell surface receptor commonly exploited 
for targeted therapy for a range of cancer types [61]. To 
investigate if the preferential uptake of HALNPs to GBM 
cells over astrocytes and MGs is driven by CD44 we first 
performed western blot to quantify total CD44 protein 
levels in all six cells types (Figure 3, Supplementary 
Figure 4). From this analysis we found that CD44 
is expressed lowest in both cerebellum and cortical 
astrocytes, higher in the GBM cells, and highest in 
the MG cells. By using the cerebellum astrocytes as a 
comparison baseline for CD44 expression, we found that 
cortical astrocytes, MG, A172, U251, and U87MG GBM 
cells had a 2, 5, 3.3, 3.8, and 3.9 fold higher expression, 
respectively. This data agrees with recent findings that 
CD44 expression is increased in glioma cells as compared 
to healthy astrocytes [23, 24]. Furthermore, the high 
expression of CD44 in MG cells was not surprising 
because CD44 has been shown to play a role in regulation 
of macrophage phagocytosis and inflammation pathways 
[62, 63]. We hypothesize that the CD44 receptors on the 
MG cells are not functional compared to the ones on 
GBM cells (at least to high MW HA). Recent studies have 
demonstrated that CD44 functionality, not necessarily 
the expression, defines its potential for targeted therapy 
[64]. We believe that this might be the potential reason 
for lower uptake of HALNPs in MG cells even when the 
CD44 expression is the highest in the cells. 
A saturation experiment was then performed to 
precisely block the CD44 receptor to discern if the 
increase in total CD44 expression translated to a higher 
uptake of the HALNPs (Figure 4). Each of the cell types 
was pre-treated with excess HA prior to the addition of 
the HALNPs, and then the per-cell fluorescence was 
directly compared between the pre-treated and non-pre-
treated samples. The percent difference in uptake was 
Table 1: Size and charge characterization of the lipid nanocarrier pre and post surface decoration 
with high molecular weight HA
Hydrodynamic Diameter (nm) Polydispersity Index Zeta Potential (mV)
LNP 95.0 ± 0.7 0.032 −5.74 ± 2.24
HALNP 126.6 ± 5.62 0.157 −23.64 ± 1.49
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then used as a quantitative measure as to the capacity 
of each specific cell type to employ CD44-HA receptor 
endocytosis of the HALNPs. From this analysis we 
found that both cerebellum and cortical astrocytes do not 
internalize HALNPs via a CD44 driven route, and thus 
any uptake into these cells must be facilitated by non-
specific interactions. Similarly, HA pre-treatment did 
not significantly influence HALNP uptake in MG cells 
Figure 2: HALNP uptake rate and extent in glioblastoma, astrocytes and microglial cells. Flow cytometry was employed to 
measure HALNP uptake via (A) histogram, (B) population wide, and (C) per-cell fluorescence following a 3 and 12 hour incubation time 
in cerebellum astrocytes (Cereb Astro), cortical astrocytes (Cort Astro), microglial (MG), and three glioblastoma cell lines (A172, U251, 
and U87MG) (**p < 0.005, *p < 0.05 relative to both astrocytes and MG at the same time point; ##p < 0.005, #p < 0.05 relative to the same 
cell type at the previous time point; n = 4). For each cell type, control cells (no HALNPs) were used to create a lower limit-gating event 
to remove cell specific auto-fluorescence. (D) Quantitative confocal microscopy was also performed following an analogous three hours 
incubation time with HALNPs to validate the flow uptake data. The confocal scale bars at 50 micron.
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although they exhibited the highest total CD44 expression. 
We postulate this is due to the vast amount of different 
uptake mechanisms employed by MG for immune defense, 
as well as possible activation state of the MG cells. In 
contrast, A172, U251, and U87MG GBM cells were found 
to significantly employ CD44 stimulated uptake yielding 
a percent difference in per-cell fluorescence of 36%, 48%, 
and 76%, respectively. Following validation that CD44 
facilitates targeted GBM uptake, we next investigated how 
the CD44 pathway influences intracellular distribution of 
the HALNPs.
CD44 stimulated uptake of HALNPs leads to 
endolysosomal escape in GBM cells 
Nanoscale drug delivery systems are commonly 
hindered in application by inefficient intracellular delivery 
and subsequent lysosome driven degradation [65]. 
Therefore, recent efforts have focused on finding ways 
to simultaneously facilitate targeted uptake and evade 
lysosome localization [66]. To examine the intracellular 
distribution of HALNPs as a function of CD44 receptor 
employment, we performed live cell confocal microscopy 
Figure 3: CD44 protein expression analysis in six cells in the GBM tumor microenvironment. cerebellum astrocytes 
(Cereb Astro), cortical astrocytes (Cort Astro), microglial (MG), and three glioblastoma cell lines (A172, U251, and U87MG) (**p < 0.005, 
*p < 0.05 relative to both Cereb Astro and Cort Astro; n = 3). GAPDH was used as the loading control.
Figure 4: CD44 receptor saturation investigation on the rate of per cell fluorescent HALNP uptake. Excess HA was 
used to saturate CD44 receptors, allowing for the direct quantification of CD44 mediated HALNP endocytosis capacity of each cell type 
(**p < 0.005, *p < 0.05; n = 4). Three hour time point shown.
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to visualize the HALNP-lysosome co-localization 
patterns. The goal of this experiment was to directly test 
if cells that exploit CD44 driven uptake (GBM cells) have 
different HALNP intracellular fate than that of cells that 
do not readily utilize CD44 (astrocytes, and to a lesser 
extent MG). For this analysis, we chose cortical 
astrocytes, MG, and A172 as representative cells for 
each cell type, and incubated the cells with HALNPs for 
five hours prior to confocal investigation. Using high 
magnification confocal microscopy and z axis slicing 
(Figure 5A), we observed that cortical astrocytes and 
MG cells displayed extensive HALNP co-localization 
with lysosomes. This high occurrence of co-localization 
was expected in cortical astrocytes and MG cells 
because a majority of non-specific uptake mechanisms 
except caveolae- culminate their endocytosis pathway 
by fusion with lysosomes [67]. Alternatively, the A172 
cells had significantly less HALNP co-localization with 
lysosomes following intracellular delivery. This evasion 
of lysosomal degradation agreed with our previous 
findings of HALNP intracellular fate with breast cancer 
cells that also strongly employ CD44 mediated uptake 
[22], as well as other studies using HA as a targeting 
moiety [68–70]. To further authenticate that the HALNPs 
achieved cytoplasmic escape in the A172 cells following 
CD44 driven uptake, we then performed confocal 
microscopy with z-axis transformation (Figure 5B). 
This technique allowed for the direct visualization of 
HALNPs in comparison to an internal reference frame 
(in our case the cell nucleus), and fostered confidence that 
HALNPs achieved homogenous cytoplasmic distribution 
with minimal lysosomal co-localization. Following this 
in-depth confocal analysis, we began to hypothesize that 
the combination of preferential uptake and lysosomal 
Figure 5: Investigation of HALNP intracellular fate in healthy glial versus GBM cells. (A) Live cell confocal microscopy with 
z-axis stacking to probe the HALNP (green) and lysosome (red) co-localization patterns (overlay color = orange). (B) Z-axis transformation 
analysis with optical zoom to validate lysosomal evasion and subsequent achievement of homogenous cytoplasmic distribution in the A172 
GBM cell. The cell nucleus was used as an internal reference point (The XZ and YZ planes show the cell height and width, and height and 
length respectively). For both confocal analyses a five hour incubation time was implemented and the scale bar is 10 micron.
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evasion in GBM cells as opposed to the non-specific 
uptake and lysosomal co-localization of healthy glial cells 
may lead to enhanced potency and reduced offsite toxicity 
for HALNP facilitated GBM therapy.
HALNPs increase the delivery selectivity and 
overall efficacy of chemotherapeutic GBM 
therapy
The therapeutic potential of HA as a targeting ligand 
for GBM treatment was directly tested by encapsulating 
Doxorubicin into the HALNPs and performing a 
24 hour potency assay with cortical astrocytes, MG, and 
A172 cells. Doxorubicin (DOX) was chosen as a model 
chemotherapeutic cargo due to its broad cancer therapy 
repertoire, including efforts at GBM management [71, 72]. 
Following our previous protocol for DOX encapsulation 
into the HALNPs (HALNP-DOX) [57], a Lipid:DOX mass 
ratio of 2.88:1 was achieved and the final DOX loaded 
particles were 167.8 ± 9.2 nm in size, −21.19 ± 5.2 mV 
in charge, and had a PI of 0.241. We seeded the three cell 
types overnight and then performed a potency assay the 
next morning over the DOX range (encapsulated DOX) 
of 0 to 10 μg/ml. Following the 24 hour incubation time, 
a standard MTT viability assay was used to determine 
the lethal concentration to kill 50% of the cell population 
(LC50) (Figure 6). This assay demonstrated that the 
LC50 of HALNP encapsulated DOX for the A172 cells 
was nearly 5 fold lower than the LC50 for the cortical 
astrocytes, and nearly 3 fold lower than the LC50 for the 
MG cells. Specifically, the LC50 values were found to be 
0.511 ± 0.039, 0.317 ± 0.048, and 0.114 ± 0.010 μg/ml 
DOX for the Cort astro, MG, and A172 cells, respectively 
(Table 2). This result was extremely exciting because it 
clearly shows the significant advantage of employing HA 
as an active GBM targeting ligand.
To further probe the specificity of HA mediated 
targeting, we also performed a 24 hour potency assay 
with the three cells types utilizing DOX in its free form, 
not associated with a nanocarrier, over the analogous 
concentration range (Supplementary Figure 5). From this 
assay we found that DOX was less potent in the cortical 
astrocytes and most potent in the A172 cells. The LC50 
values were measured to be 0.322 ± 0.053, 0.267 ± 0.050, 
and 0.193 ± 0.030 μg/ml DOX for the Cort astro, MG, 
and A172 cells, respectively (Table 2). These results are 
possibly due to the mechanism of action of DOX that 
includes interfering with the replication process, thus 
resulting in greater toxicity in more rapidly dividing 
cells. In addition to providing valuable data regarding 
the potency of DOX in its free form, this experiment also 
validated the targeting capacity of HA. By comparing 
the HALNP-DOX LC50 to the free DOX LC50 for each 
specific cell type, the therapeutic influence of specificity 
was quantified. For the cortical astrocytes, the LC50 value 
significantly increased 59% by utilizing the HALNP 
system over free DOX. Similarly, LC50 value increased 
by 19% by due to delivery of DOX encapsulated in the 
HALNPs system to the MG cells. These results exemplify 
that the HALNP nanoparticles are not readily internalized 
into healthy glial cells, and thus the HALNP nanocarrier 
may reduce the chance of offsite toxicity for GBM 
Figure 6: Potency assay employing doxorubicin (DOX) to investigate the influence of HALNP targeting specificity and 
endolysosomal escape on therapeutic efficacy. HALNP encapsulated DOX (HALNP-DOX) potency was compared between glial 
(cortical astrocytes-Cort Astro and microglial-MG) and GBM (A172) cells following a 24 hour incubation time (n = 3).
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therapy. However, the LC50 value decreased significantly 
by 41% for the A172 GBM cells via employment of the 
HALNP system. This experiment confirmed that the 
HALNP system increases the overall efficacy and safety 
of chemotherapeutic GBM therapy. Furthermore, the 
acquired results agree with another study that found that 
HA targeted liposomes increased the potency of DOX 
for CD44 positive melanoma, but decreased the potency 
of DOX when the CD44 active uptake mechanism was 
removed [73]. 
CONCLUSIONS
In conclusion, this study has demonstrated the 
vast potential of HA facilitated active targeting for GBM 
nano-therapy. Although the cell surface receptor CD44 
has been found to be increased in GBM cells, only a few 
studies have been conducted implementing HA decorated 
nanocarriers for GBM treatment. Furthermore, no studies 
to date have performed an in-depth analysis probing the 
true merit of HA as a natural ligand to favorably target 
GBM cells over healthy glial cells. This is the first 
study known to the authors to employ a comprehensive 
in vitro brain model containing healthy glial cells such 
as astrocytes and microglia as well as multiple types of 
glioblastoma cells in combination with a translational 
HA coated nanocarrier to test the targeting capacity and 
specificity of HA for GBM treatment. From this analysis 
we found that HA promotes preferential uptake, facilitates 
intracellular lysosomal evasion, and significantly enhances 
chemotherapeutic potency in GBM cells while eluding 
uptake in astrocytes and MG cells. We believe these 
findings are significant and will promote the widespread 
implementation of HA for nanoscale GBM therapy and 
other brain malignancies. In addition to nanocarriers, 
we believe these results will also further catalyze CD44 
inhibitors as a method for GBM suppression. In the 
future we plan on harnessing the GBM targeting power 
of HALNPs with our previously optimized substrate 
mediated HALNP delivery platform (HALNP-PEM) [57] 
to create an implantable device to occupy the cavity of 
resected GBM tumors to promote local, sustained, and 
targeted therapy and thus bring visible advancement to 
GBM management.
MATERIALS AND METHODS
Materials
For hyaluronic acid coated liposome nanoparticle 
creation, high molecular weight hyaluronic acid 
(HA) (~1.65 MDa), 1, 2- Dipalmitoyl-sn-Glycero-3-
Phosphoethanolamine (DPPE), Cholesterol (CHOL), and 
1-ethyl-3-(3-dimethylaminopropyl) carbomiide (EDAC) 
were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Additionally, L α-Phosphatidylcholine (PC), Top Fluor 
fluorescently conjugated cholesterol (FCHOL), and a 
mini-extruder apparatus were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). For flow cytometry 
analysis, flow cytometry tubes were purchased from 
Becton Dickenson (Franklin Lakes, NJ, USA). For cell 
culture, all tissue culture petri substrates were purchased 
from Fisher (Waltham, MA, USA).
Lipid nanoparticle fabrication and hyaluronic 
acid surface decoration
Multilamellar vesicles were made from PC, 
DPPE, and CHOL in a 3:1:1 molar ratio and doped with 
0.15 mass% FCHOL (as a tracker) by applying the dry lipid 
film technique, mechanically extruded to the nanoscale, 
and surface decorated with HA as described earlier [22, 57]. 
Briefly, extrusion was carried out in a stepwise manner 
at 65°C ensuring product homogeneity and a final lipid 
nanoparticle (LNP) diameter in the 80–100 nm range. 
Following LNP purification via ultracentrifugation to 
remove any excess lipid debris (1.5 hr, 135,000 g), the 
primary amine of the DPPE lipid head group was amide 
bonded to the carboxylic acid group of EDC-activated 
HA to form HA decorated LNPs (HALNPs) following 
standard crosslinking protocol. The HALNPs were then 
purified form excess crosslinking reagents and either 1) 
stored at 4°C and used within 2 weeks of creation or 2) 
snap froze and lyophilized following previous protocol 
for drug entrapment experiments [22]. Lyophilized HA 
coated particles were observed to be stable for over two 
months when stored at −80°C (Supplementary Table 1). 
To determine the effect of HALNP membrane fluidity on 
the kinetics of drug release, the molar ratio of cholesterol 
Table 2: Potency assay with doxorubicin (DOX) LC50 values (μg/ml) following the 24 hour 
incubation time
Free DOX HALNP-DOX
Cort Astro 0.322 ± 0.053 0.511 ± 0.039
MG 0.267 ± 0.050 0.317 ± 0.048
A172 0.193 ± 0.030 0.114 ± 0.010
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was varied from 20 to 25 % and a model therapeutic cargo, 
FITC tagged Dextran, was encapsulated into the aqueous 
core of the HALNPs following previous protocol [22] 
(Supplementary Figure 6). Although the higher cholesterol 
formulation extended drug release profiles, this higher 
cholesterol content was found to reduce encapsulation 
efficiency. As a result, 20 mol % particles were chosen as 
the optimized HALNP composition. 
Dynamic light scattering and zeta potential 
characterization
Hydrodynamic diameter and zeta potential of 
the LNPs and HA coated LNPs was measured using a 
Brookhaven NanoBrook ZetaPALS zeta potential and 
dynamic light scattering instrument (Holtsville, NY, 
USA). The nanoparticle size was measured as an intensity 
averaged distribution using a scattering angle of 90°. The 
Smoluchowki model was utilized to calculate the zeta 
potential from mobility measurements. All measurements 
were performed in 0.05 × PBS (pH 7.4) at 25°C.
Transmission electron microscopy
The phosphotungstic negative stain method was 
utilized for visualization of the LNP system following 
previous protocol [22]. A drop of either LNP or HALNP 
was applied to a carbon film coated copper grid and left 
to air dry at room temperature. Phosphotungstic acid 
solution promoted negative staining, and the samples were 
analyzed in the UNL Microscopy Core Research Facility’s 
TEM model Hitachi H7500 (Chiyoda, Tokyo, Japan).
Cell culture
All cells were cultured in aseptic conditions 
following standard cell culture protocol and stored in an 
incubator set at 37°C with 5% CO2.
Primary cortical and cerebellum astrocytes
Primary cortical (Cort) and cerebellum (Cereb) 
astrocytes were prepared from 1–2 day-old Charles River 
(Wilmington, MA, USA) Sprague-Dawley rat pups from 
four donor rats yielding 12+ pups per litter in compliance 
with UNL’s IACUC protocol 1046 as described previously 
[74]. Briefly, the Cort and Cereb brain regions were 
isolated, digested with trypsin and DNase, filtered through 
a 70 micron filter, centrifuged, and suspended in complete 
culture media prior to seeding. The Cort and Cereb 
Astrocytes were cultured in DMEM/F12 supplemented 
with 10% FBS and 1% PS from Life Technologies (Grand 
Island, NY, USA).
Primary microglia (MG)
Mouse microglia were grown in macrophage serum 
free media containing L-glutamine and supplemented 
with 10% FBS and 1% PS. Additionally, recombinant 
mouse granulocyte macrophage colony stimulating factor 
(GM-CSF) from Life Technologies was added to each 
seeded flask at a concentration of 10 ng/ml and replenished 
every 3 days.
GBM cell lines
A172 (ATCC: CRL1620) human glioblastoma cell 
line was grown in DMEM/F12 supplemented with 10% 
FBS and 1% PS. U251 (Sigma) human glioblastoma 
astrocytoma and U87MG (ATCC: HTB14) human grade 
IV astrocytoma/glioblastoma cell lines were grown in 
MEM media supplemented with 10% FBS, 1% PS, 1% 
NEAA, and 1 mM Sodium Pyruvate (all stated reagents 
from Thermo Scientific; Waltham, MA, USA).
Flow cytometry
Flow cytometry was performed employing a 
FACSCantoII from Becton Dickenson (Franklin Lakes, 
NJ, USA). Each of the six cell types of the in vitro brain 
model were seeded at a density of 100,000 cells per well 
in a 12 well plate layout and allowed to incubate overnight 
to facilitate cell attachment. After this incubation time, 
HALNPs fluorescently doped with 0.15 mass % FCHOL 
as a tracker were added to the cells at a concentration of 
105 µg lipid per well and incubated for 3 or 12 hours. 
Directly after this incubation time, the cells were washed 
three times with sterile 1X PBS, trypsinized, and measured 
for per cell and population wide fluorescence (ex. 495, 
em. 520; 10,000 total events/read). By reading control 
cells without the addition of HALNPs, a lower limit 
gating event was created to remove cell specific auto 
fluorescence.
Confocal microscopy
An Inverted confocal microscope (Olympus IX 81) 
at the UNL Microscopy Core Research Facility was used 
for four separate experiments:
Confocal of the fluorescently tagged HALNPs
FCHOL doped HALNPs were diluted to 55 ng/ml in 
1× PBS and the solution was viewed at 100× magnification 
with optical zoom using a cover slip (ex. 495, em. 520).
Quantitative HALNP Uptake between the in Vitro 
brain model
Cort Astro, Cereb Astro, MG, A172, U251, and 
U87MG cells were seeded at 230,000 cells per 35 mm glass 
bottom dish from Mattek (Ashland, MA, USA) overnight 
to promote cell attachment. The next morning, 1.58 mg/ml 
HALNP was added per dish and incubated for 3 hours. 
During the final half hour of the incubation, cellular nuclei 
were stained with Hoerscht (Thermo Scientific) following 
stated protocol. Subsequent to the staining procedure, 
each dish was washed 3× with sterile 1× PBS and kept 
in HEPES buffered media without phenol red during the 
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confocal visualization. A constant laser intensity was used 
to take photos at 20× and 60× for each cell type for a 
quantitative measurement of HALNP uptake.
Lysosomal co-localization
Cort Astro, MG, and A172 cells were seeded at 
230,000 cells per 35 mm glass bottom dish from Mattek 
overnight to promote cell attachment. The next morning, 
1.58 mg/ml HALNP was added per dish and incubated for 
5 hours, and the intracellular lysosomes and nuclei were 
stained following previous protocol [22]. Following this 
incubation time, the cells were washed and visualized at 
100×. Z-axis slices were merged to display the occurrence 
of HALNP-lysosome co-localization in each cell type.
Z-axis transformation with A172 Cells
A172 cells were seeded at 230,000 cells per glass 
bottom plate, incubated with 1.58 mg/ml HALNP for 
five hours, and the lysosomes and nuclei were stained. 
A Z-axis transformation was then performed (100× 
with optical zoom) using the stained cell nucleus as an 
internal reference point. From this analysis, an XZ and 
YZ plan were constructed to directly visualize cytoplasmic 
HALNPs.
Western blot
Total protein was extracted from Cort Astro, Cereb 
Astro, MG, A172, U251, and U87MG cells cultured on 
standard TCPS surfaces by RIPA buffer induced cell 
lysis and protein solubilization followed by the scraping 
method. Western blotting was used to determine the 
expression of the cell surface receptor CD44 in each of 
the six brain cells. BCA protein quantification kit from 
Abcam (Cambridge, MA, USA) was used to quantify total 
protein concentration, 25 μg total protein was loaded per 
lane, the blot was run on a 7.5% tris-glycine SDS PAGE 
homemade gel, the membrane was probed for CD44 
(Abcam; ab24504), and protein bands were developed 
and quantified by use of a LI-COR (Lincoln, NE, USA) 
Odyssey FC and Image Studio Lite ver. 5.0 software, 
respectively. GAPDH (Millipore; ABS16) expression was 
measured as a normalization control for loading.
Saturation of CD44 receptor (competition assay)
Cort Astro, Cereb Astro, MG, A172, U251, and 
U87MG cells were seeded overnight at a density of 
100,000 cells per well in a 12 well plate. The next morning, 
250 μg of HA was added to select wells and incubated for 
1 hour at 37°C. Following this pre-treatment procedure, 
105 μg fluorescently doped HALNPs were incubated with 
the cells for three hours and then flow cytometry analysis 
was used to directly measure the difference in per cell 
fluorescence between the HA pre-treated samples and non 
HA-pretreated samples (of analogous HALNP incubation 
time and concentration).
DOX potency assay
Encapsulation of DOX into HALNPs
Doxorubicin (DOX) was encapsulated inside the 
aqueous core of the HALNPs as previously described 
[57]. Briefly, a vial of lyophilized HALNPs (0.5 mg lipid) 
was brought to room temperature, and rehydrated with 
1/10th its original pre-lyophilized volume of 0.05 × PBS 
containing 250 μg DOX. Following a thirty minute 
incubation time to allow for lipid membrane re-assembly, 
the vial was brought back to its full pre-lyophilized 
volume with 1 × PBS and ultracentrifuged to remove 
non-encapsulated DOX (140,000 g, 4°C, and 1.25 hr.). 
The auto-fluorescent nature of DOX was then employed 
to determine the entrapment payload. A standard curve 
consisting of a known amount of DOX was compared to 
0.1% triton X-100 permeabilized HALNPs to determine 
the total encapsulated DOX. A final lipid to DOX mass 
ratio of 2.88 to 1 was achieved with a 69.4% encapsulation 
efficiency. These purified DOX containing particles are 
referred to as HALNP-DOX.
Cell seeding and HALNP-DOX addition
Cort Astro, MG, and A172 cells were seeded in 
a 48 well plate at a density of 35,000 cells per well and 
incubated overnight to facilitate cell attachment. The next 
day following validation of homogenous cell attachment, 
DOX in its free form (not associated with a nanocarrier) 
or HALNP-DOX were added to select wells in a 
concentration range of 0 to 10 μg/ml and left to incubate 
for an additional 24 hours.
Free DOX and HALNP-DOX potency determination 
– MTT assay
To determine the effect of free DOX and HALNP-
DOX on the cell viability of Cort Astro, MG and A172 
cells, we utilized an MTT assay as previously reported to 
calculate the lethal concentration to kill 50% of the cells 
[57, 74, 75]. Following the 24 hour DOX incubation time, 
the medium of the cells was aspirated, and sterile 5 mg/ml 
MTT working solution was added and incubated for 
2 hours at 37°C. The cells were then lysed with acidified 
IPA and the absorbance of the produced formazan crystals 
was measured using a Beckman Coulter AD340 plate 
reader (Indianapolis, IN, USA). Percent viability was 
determined by normalization of the 570/620 absorbance 
ratio to the control untreated cells and positive control 
dead cells (ethanol treated). 
Statistical analysis
The difference between experimental groups was 
investigated by a one-way analysis of variance (ANOVA) 
and by a subsequent Turkey’s multiple comparison test in 
Sigma Plot Software. For statistical analysis of all data, 
p < 0.05 was regarded as the lowest acceptable threshold 
for significance.
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